
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

Merck is to collaborate on drug development with biotech firm NGM Pharmaceuticals in a $450 million deal. The collaboration will …

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

A ‘tattoo-like’ ultra-thin sensor that sits on the skin has been developed that could help patients monitor their blood glucose …

The US Food and Drug Administration has shown the green light to US firm EnteroMedics’ new obesity device VBLOC that …

Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …

The US Food and Drug Administration has shown Novo Nordisk’s obesity drug Saxenda the green light to aid chronic weight …
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …

Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …

The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Novo Nordisk has invested $130 million in new diabetes laboratories as the company looks to focus more strongly on the …

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …